Genetically Engineered Mouse Models of PI3K Signaling in Breast Cancer

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2013 Mar 13

PMID 23478237

Citations 23

Authors

Sjoerd Klarenbeek

Martine H van Miltenburg

Jos Jonkers

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common type of cancer in women. A substantial fraction of breast cancers have acquired mutations that lead to activation of the phosphoinositide 3-kinase (PI3K) signaling pathway, which plays a central role in cellular processes that are essential in cancer, such as cell survival, growth, division and motility. Oncogenic mutations in the PI3K pathway generally involve either activating mutation of the gene encoding PI3K (PIK3CA) or AKT (AKT1), or loss or reduced expression of PTEN. Several kinases involved in PI3K signaling are being explored as a therapeutic targets for pharmacological inhibition. Despite the availability of a range of inhibitors, acquired resistance may limit the efficacy of single-agent therapy. In this review we discuss the role of PI3K pathway mutations in human breast cancer and relevant genetically engineered mouse models (GEMMs), with special attention to the role of PI3K signaling in oncogenesis, in therapeutic response, and in resistance to therapy. Several sophisticated GEMMs have revealed the cause-and-effect relationships between PI3K pathway mutations and mammary oncogenesis. These GEMMs enable us to study the biology of tumors induced by activated PI3K signaling, as well as preclinical response and resistance to PI3K pathway inhibitors.

Citing Articles

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.

Tufail M, Hu J, Liang J, He C, Wan W, Huang Y J Transl Med. 2024; 22(1):15.

PMID: 38172946 PMC: 10765967. DOI: 10.1186/s12967-023-04841-w.

Investigating the Role of Heparanase in Breast Cancer Development Utilising the MMTV-PyMT Murine Model of Mammary Carcinoma.

Jayatilleke K, Duivenvoorden H, Ryan G, Parker B, Hulett M Cancers (Basel). 2023; 15(11).

PMID: 37297024 PMC: 10253202. DOI: 10.3390/cancers15113062.

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.

Kumar H, Gupta N, Jain R, Madhunapantula S, Babu C, Kesharwani S J Adv Res. 2023; 54:271-292.

PMID: 36791960 PMC: 10703733. DOI: 10.1016/j.jare.2023.02.005.

Generation of a tree shrew breast cancer model using lentivirus expressing - .

Zeng L, Zhang H, Yang C, Cheng Z, Jiang Q, Luo Y Zool Res. 2022; 44(1):94-97.

PMID: 36376241 PMC: 9841197. DOI: 10.24272/j.issn.2095-8137.2022.240.

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.

Vasan N, Cantley L Nat Rev Clin Oncol. 2022; 19(7):471-485.

PMID: 35484287 PMC: 11215755. DOI: 10.1038/s41571-022-00633-1.

References

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

Utermark T, Rao T, Cheng H, Wang Q, Lee S, Wang Z . The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012; 26(14):1573-86. PMC: 3404385. DOI: 10.1101/gad.191973.112. View

Derose Y, Wang G, Lin Y, Bernard P, Buys S, Ebbert M . Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17(11):1514-20. PMC: 3553601. DOI: 10.1038/nm.2454. View

Staal S . Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987; 84(14):5034-7. PMC: 305241. DOI: 10.1073/pnas.84.14.5034. View

Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar K . Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene. 2012; 32(3):318-26. PMC: 3550595. DOI: 10.1038/onc.2012.53. View

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

Davies B, Greenwood H, Dudley P, Crafter C, Yu D, Zhang J . Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012; 11(4):873-87. DOI: 10.1158/1535-7163.MCT-11-0824-T. View

Razis E, Bobos M, Kotoula V, Eleftheraki A, Kalofonos H, Pavlakis K . Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011; 128(2):447-56. DOI: 10.1007/s10549-011-1572-5. View

Schwertfeger K, Richert M, Anderson S . Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol. 2001; 15(6):867-81. DOI: 10.1210/mend.15.6.0663. View

10.

Lauchle J, Kim D, Le D, Akagi K, Crone M, Krisman K . Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009; 461(7262):411-4. PMC: 4119783. DOI: 10.1038/nature08279. View

11.

Dow L, Lowe S . Life in the fast lane: mammalian disease models in the genomics era. Cell. 2012; 148(6):1099-109. PMC: 3410373. DOI: 10.1016/j.cell.2012.02.023. View

12.

Zagouri F, Sergentanis T, Chrysikos D, Filipits M, Bartsch R . mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol. 2012; 127(3):662-72. DOI: 10.1016/j.ygyno.2012.08.040. View

13.

Panigrahi A, Pinder S, Chan S, Paish E, Robertson J, Ellis I . The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004; 204(1):93-100. DOI: 10.1002/path.1611. View

14.

Berger A, Knudson A, Pandolfi P . A continuum model for tumour suppression. Nature. 2011; 476(7359):163-9. PMC: 3206311. DOI: 10.1038/nature10275. View

15.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

16.

Singh M, Lima A, Molina R, Hamilton P, Clermont A, Devasthali V . Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010; 28(6):585-93. DOI: 10.1038/nbt.1640. View

17.

Dumont A, Dumont S, Trent J . The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer. 2012; 31(7):327-34. PMC: 3777497. DOI: 10.5732/cjc.012.10032. View

18.

Young C, Nolte E, Lewis A, Serkova N, Anderson S . Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res. 2008; 10(4):R70. PMC: 2575543. DOI: 10.1186/bcr2132. View

19.

Tikoo A, Roh V, Montgomery K, Ivetac I, Waring P, Pelzer R . Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS One. 2012; 7(5):e36924. PMC: 3364244. DOI: 10.1371/journal.pone.0036924. View

20.

Beelen K, Zwart W, Linn S . Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol. 2012; 9(9):529-41. DOI: 10.1038/nrclinonc.2012.121. View